多发性骨髓瘤(MM)系一种浆细胞恶性克隆增殖性疾病,骨髓内大量浆细胞增生,并分泌单克隆免疫球蛋白,目前治疗仍以化疗为主,但由于MM患者年龄偏大,对化疗耐受性差,花费较高,且多次化疗易产生交叉耐药,容易复发,MM患者较少选择治疗而困扰着临床。有研究表明[1]沙利度胺(反应停)对 Multiple myeloma (MM) is a malignant clone proliferative disease of plasma cells, a large number of plasma cells in the bone marrow hyperplasia, and the secretion of monoclonal immunoglobulin, the current treatment is still based chemotherapy, but due to older patients with MM, the right Chemotherapy tolerance is poor, high cost, and multiple chemotherapy prone to cross-resistance, easy to relapse, MM patients less choice treatment plagued clinical. Some studies have shown that [1] thalidomide (reaction stop) on